EMEA-001493-PIP02-18

Key facts

Invented name
Xalkori
Active substance
crizotinib
Therapeutic area
Oncology
Decision number
P/0361/2018
PIP number
EMEA-001493-PIP02-18
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of lung malignant neoplasms
Route(s) of administration
Oral use
Contact for public enquiries
Pfizer Limited

Tel. +44 (0)1304 646 607
E-mail: pip_enquiries@pfizer.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating